Indeed, antiangiogenic therapy with bevacizumab, antibodies against vascular endothelial growth factor A (VEGF-A), or tyrosine kinase inhibitors such as sunitinib and pazopanib have been shown to effectively control metastatic breast cancer [14]. This evidence concerns the gene VEGFA and breast cancer.